Q702 for the Treatment of Patients With Hematologic Malignancies

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Trial Details

NCT ID
NCT06712810
Phase
PHASE1
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Axl/Mer/CSF1R Inhibitor Q702
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Magnetic Resonance Imaging
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • PRE-REGISTRATION: Age ≥ 18 years
  • PRE-REGISTRATION: Not eligible for or have failed therapies with established benefits, at the discretion of the treating physician
  • PRE-REGISTRATION: Patients must meet one of the following criteria:
  • Relapsed/refractory patients with Erdheim-Chester disease, Langerhans histiocytosis, histiocytic sarcoma, or other malignant histiocytosis without …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →